Camp4 Therapeutics Corporation
CAMP
$4.36
$0.163.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 271.84% | -56.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 271.84% | -56.23% | |||
| Cost of Revenue | 21.57% | -10.68% | |||
| Gross Profit | -10.70% | 6.45% | |||
| SG&A Expenses | -11.79% | 3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.46% | -5.93% | |||
| Operating Income | -2.31% | 2.90% | |||
| Income Before Tax | 54.50% | -166.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.50% | -166.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.50% | -166.80% | |||
| EBIT | -2.31% | 2.90% | |||
| EBITDA | -1.19% | 2.65% | |||
| EPS Basic | 57.69% | -35.12% | |||
| Normalized Basic EPS | 57.69% | -39.68% | |||
| EPS Diluted | 57.69% | -35.12% | |||
| Normalized Diluted EPS | 57.69% | -39.68% | |||
| Average Basic Shares Outstanding | 7.55% | 97.47% | |||
| Average Diluted Shares Outstanding | 7.55% | 97.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||